Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations

PURPOSE: Although EGFR-mutated patients generally do not benefit from checkpoint inhibitors (ICIs), some patients in the KEYNOTE-001 study consistently benefited from this treatment. This study investigated immune microenvironment characteristics to identify the subgroup of patients that may benefit...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Wang, Chen, Naifei, Li, Lingyu, Chen, Xiao, Liu, Xiangliang, Zhang, Yongfei, Cui, Jiuwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490071/
https://www.ncbi.nlm.nih.gov/pubmed/32982525
http://dx.doi.org/10.2147/LCTT.S262822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490071/
https://www.ncbi.nlm.nih.gov/pubmed/32982525
http://dx.doi.org/10.2147/LCTT.S262822

Ejemplares similares